Last chance to save on Digiday Publishing Summit passes is February 9
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
Facing ‘AI slop’ and a trust problem, AI platforms invest in Super Bowl-level brand ads
To fight distrust and ‘AI slop,’ AI platforms are investing heavily in brand advertising.
Retailers, brands face a test: Oppose ICE or stay quiet while thousands protest
Up until a few days ago, Target and other major employers in Minnesota had refrained from speaking out on ICE’s presence in the state.
Digiday staffers tackle the creator vs. influencer divide
Creator vs. influencer: Digiday staffers debate the difference, and why it matters to marketers on this episode of the Digiday Podcast.